Abstract
Although it has been more than 20 years since Moehlig first used adrenal cortical extracts in the treatment of a patient with myasthenia gravis and reported dramatic improvement 1 the usefulness of corticotropin (ACTH) and corticosteroids in the treatment of this disease remained unsettled. Osserman 2 described them as drugs to be used with extreme caution, and Schwab 3 considered them still of questionable value. Why is there not a clearer understanding of the efficacy of these agents? This is partly because of the vagaries of the disease, ranging from apparently spontaneous remissions to sometimes equally sudden relapses. It is partly because of enthusiasms, the enthusiasm of the patient with his fervor to respond to a new treatment and the enthusiasm of the physician with his eagerness to help his patient. And partly, emphasized by the vagaries and the enthusiasms, it is because of inadequate trials. Perusal of the published
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
